These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 4903342)

  • 1. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
    Siegfried J; Klaiber R; Perret E; Ziegler WH
    Dtsch Med Wochenschr; 1969 Dec; 94(52):2678-81. PubMed ID: 4903342
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D
    Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 4. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 6. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

  • 9. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 11. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
    Birkmayer W
    Wien Klin Wochenschr; 1969 Sep; 81(39):677-9. PubMed ID: 5344299
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 14. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
    Rinne UK; Sonninen V; Sirtola T
    Z Neurol; 1972; 202(1):1-20. PubMed ID: 4114458
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 19. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1969 Dec; 197(1):85-100. PubMed ID: 5364658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.